Cargando…

Risk stratification in therapy-related myelodysplastic syndromes

Detalles Bibliográficos
Autor principal:	Zeidan, Amer M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655180/ https://www.ncbi.nlm.nih.gov/pubmed/29113285 http://dx.doi.org/10.18632/oncotarget.21178

Ejemplares similares

Editorial: Risk-stratification in myelodysplastic syndromes
por: Breccia, Massimo, et al.
Publicado: (2022)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
por: Abou Zahr, Abdallah, et al.
Publicado: (2014)

Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
por: Stahl, Maximilian, et al.
Publicado: (2020)

Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
por: Mosquera Orgueira, Adrian, et al.
Publicado: (2023)

Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
por: Lewis, Russell, et al.
Publicado: (2021)

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
por: Kuendgen, A., et al.
Publicado: (2020)

Myelodysplastic Syndrome in Pakistan: Clinicohematological Characteristics, Cytogenetic Profile, and Risk Stratification
por: Mahmood, Rafia, et al.
Publicado: (2018)

Targeting age-related inflammation in myelodysplastic syndromes
por: Mei, Yang, et al.
Publicado: (2018)

P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
por: Zeidan, Amer M., et al.
Publicado: (2023)

PB2026: ROLE OF MOLECULAR PROFILING IN MYELODYSPLASTIC SYNDROME IN REAL-WORLD - A NEW APPROACH IN MYELODYSPLASTIC SYNDROME’S RISK STRATIFICATION?
por: Silva, Duarte Pacheco, et al.
Publicado: (2023)

The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification
por: Peng, Xiaohuan, et al.
Publicado: (2022)

Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
por: Mohty, Razan, et al.
Publicado: (2022)

How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
por: Gurnari, Carmelo, et al.
Publicado: (2022)

More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes
por: Shallis, Rory M., et al.
Publicado: (2018)

PB2015: DIAGNOSIS, CLASSIFICATION AND STRATIFICATION OF MYELODYSPLASTIC SYNDROMES IN ALGERIA
por: Moussa, Yamina Bouchakour, et al.
Publicado: (2023)

The Circular RNA Circ-ANAPC7 as a Biomarker for the Risk Stratification of Myelodysplastic Syndrome
por: Zhou, Fang, et al.
Publicado: (2022)

Myelodysplastic Syndrome: Riding the Crest of the Wave
por: Ramos, Fernando
Publicado: (2022)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
por: Zeidan, Amer M., et al.
Publicado: (2023)

Risk stratification for melanoma
por: Olsen, Catherine M., et al.
Publicado: (2019)

Infections in Myelodysplastic Syndrome in Relation to Stage and Therapy
por: Leone, Giuseppe, et al.
Publicado: (2018)

Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With Myelodysplastic Syndromes
por: Xiao, Xia, et al.
Publicado: (2020)

Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
por: Brunner, Andrew M., et al.
Publicado: (2022)

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes
por: Zeidan, Amer M., et al.
Publicado: (2022)

Paraneoplastic Large-vessel Vasculitis Associated with Myelodysplastic Syndrome
por: Yabe, Hiroki
Publicado: (2018)

Molecular-Based Score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome
por: Coelho-Silva, Juan L., et al.
Publicado: (2021)

Overlooking Obesity Hypoventilation Syndrome: The Need for Obesity Hypoventilation Syndrome Staging and Risk Stratification
por: Randerath, Winfried J., et al.
Publicado: (2020)

Risk stratification in hypertrophic cardiomyopathy
por: Desai, Milind, et al.
Publicado: (2019)

Targeting R-loop-associated ATR response in myelodysplastic syndrome
por: Nguyen, Hai Dang, et al.
Publicado: (2019)

Knowledge of Secondary Pulmonary Alveolar Proteinosis Complicated with Myelodysplastic Syndrome
por: Ishii, Haruyuki
Publicado: (2019)

Chromosome Y loss and drivers of clonal hematopoiesis in myelodysplastic syndrome
por: Baliakas, Panagiotis, et al.
Publicado: (2021)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
por: Blum, Sabine, et al.
Publicado: (2021)

Metchnikoff’s legacy: the dysplastic nature of innate immunity in myelodysplastic syndromes
por: Greenberg, Peter L.
Publicado: (2021)

Emerging Therapies for the Myelodysplastic Syndromes
por: Canaani, Jonathan
Publicado: (2019)

PB1923: PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH HYPOMETHYLATING AGENT USE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES
por: Zeidan, A., et al.
Publicado: (2022)

Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile
por: Guarnera, Luca, et al.
Publicado: (2023)

De Novo and Therapy-Related Myelodysplastic Syndromes: Analogies and Differences
por: Leone, Giuseppe, et al.
Publicado: (2022)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5a01s120e5j0gg33hsdan0dq2r